Avi Y. Goldberg Net Worth

The estimated Net Worth of Avi Y. Goldberg is at least $448 Thousand dollars as of 18 September 2015. Avi Goldberg owns over 5,000 units of Zafgen stock worth over $53,197 and over the last 9 years Avi sold ZFGN stock worth over $394,460.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Avi Goldberg ZFGN stock SEC Form 4 insiders trading

Avi has made over 3 trades of the Zafgen stock since 2015, according to the Form 4 filled with the SEC. Most recently Avi sold 5,000 units of ZFGN stock worth $225,000 on 18 September 2015.

The largest trade Avi's ever made was selling 5,000 units of Zafgen stock on 18 September 2015 worth over $225,000. On average, Avi trades about 2,500 units every 27 days since 2015. As of 18 September 2015 Avi still owns at least 53,734 units of Zafgen stock.

You can see the complete history of Avi Goldberg stock trades at the bottom of the page.

What's Avi Goldberg's mailing address?

Avi's mailing address filed with the SEC is C/O ZAFGEN, INC., 175, PORTLAND STREET, 4TH FLOOR, BOSTON, MA, 02114.

Insiders trading at Zafgen

Over the last 10 years, insiders at Zafgen have traded over $14,218,922 worth of Zafgen stock and bought 689,531 units worth $3,998,442 . The most active insiders traders include James E Deerfield Mgmt L.P...., Bruce Booth, and Kevin P Starr. On average, Zafgen executives and independent directors trade stock every 53 days with the average trade being worth of $87,516. The most recent stock trade was executed by Thomas E. Hughes on 28 June 2018, trading 32,000 units of ZFGN stock currently worth $320,000.

What does Zafgen do?

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.

Complete history of Avi Goldberg stock trades at Zafgen

Zafgen executives and stock owners

Zafgen executives and other stock owners filed with the SEC include:

• Brian McVeigh,
  Chief Business Officer
• Frank Thomas,
  Independent Director
• Thomas Daniel,
  Independent Director
• Jonathan Leff,
  Director
• Thomas Hamilton,
  Director
• Priya Singhal,
  Head of Research and Development
• Michael Celano,
  Chief Financial Officer
• Carole Ben-Maimon,
  President, Chief Executive Officer, Director
• Joseph Truitt,
  Chairman of the Board
• Patrick Loustau,
  President
• Cameron Geoffrey Mc Donough,
  Director
• Frances K Heller,
  Director
• Robert J Perez,
  Director
• John L Lamattina,
  Director
• Dennis D Kim,
  Chief Medical Officer
• Alicia Secor,
  Chief Commercial Officer
• James E Deerfield Mgmt L.P....,
  
• Bruce Booth,
  Director
• Patricia L Allen,
  Chief Financial Officer
• James E Deerfield Mgmt L.P....,
  
• Jeffrey S. Hatfield,
  Chief Executive Officer
• Wendy Everett,
  Director
• Venture Fund Vii L P Atlas ...,
  
• Peter Barrett,
  Director
• Avi Y. Goldberg,
  Director
• Rock Ventures Lp Third Rock...,
  
• Rock Ventures Lp Third Rock...,
  
• Thomas E. Hughes,
  Chief Executive Officer
• Kevin P Starr,
  Director